(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dry Age Macular Degeneration pipeline constitutes 58+ key companies continuously working towards developing 64+ Dry Age Macular Degeneration treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Dry Age Macular Degeneration Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Age Macular Degeneration Market.

 

Some of the key takeaways from the Dry Age Macular Degeneration Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies with a considerable amount of success over the years. 
  • Dry Age Macular Degeneration companies working in the treatment market are Eyevensys, SanBio, Nanoscope Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Allegro Ophthalmics, Gyroscope Therapeutics, IVERIC bio, Alkeus Pharmaceuticals, Gemini Therapeutics, Eyestem, OliX Pharmaceuticals, and others, are developing therapies for the Dry Age Macular Degeneration treatment 
  • Emerging Dry Age Macular Degeneration therapies in the different phases of clinical trials are- EYS809, SB-623, MCO-020, RPESC RPE 4W, CPCB-RPE1, Risuteganib, GT005, Zimura, ALK-001, GEM103, Eyecyte RPE, OLX301A, EYS809, and others are expected to have a significant impact on the Dry Age Macular Degeneration market in the coming years.   
  • In November 2022, IVERIC Bio announced that the U.S. Food and Drug Administration (FDA) has grantedBreakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novelinvestigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to AgeRelated Macular Degeneration (AMD).
  • Out of the emerging Dry Age-related Macular Degeneration therapies Eyecyte RPE (Eyestem), OLX301A (OliX Pharmaceuticals), and EYS809 (Eyevensys) are in the early stages of development for Dry AMD treatment.
  • On January 13, 2022, ONL Therapeutics, announced that it had closed on its second tranche of the Company’s Series B financing. The total proceeds raised in Series B was USD 46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.

 

Dry Age Macular Degeneration Overview

Dry age-related macular degeneration (AMD) involves a gradual breakdown of macular cells over an extended period. This occurs as retinal cells decline without renewal. It’s important to note that the term ‘dry’ doesn’t imply dry eyes but rather distinguishes it from wet AMD.

 

Get a Free Sample PDF Report to know more about Dry Age Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight

 

Emerging Dry Age Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

  • EYS809: Eyevensys
  • SB-623: SanBio
  • MCO-020: Nanoscope Therapeutics
  • RPESC RPE 4W : Luxa Biotechnology
  • CPCB-RPE1: Regenerative Patch Technologies
  • Risuteganib: Allegro Ophthalmics
  • GT005: Gyroscope Therapeutics
  • Zimura: IVERIC bio
  • ALK-001: Alkeus Pharmaceuticals
  • GEM103: Gemini Therapeutics
  • Eyecyte RPE: Eyestem
  • OLX301A: OliX Pharmaceuticals
  • EYS809: Eyevensys

 

Dry Age Macular Degeneration Route of Administration

Dry Age Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Dry Age Macular Degeneration Molecule Type

Dry Age Macular Degeneration Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Dry Age Macular Degeneration Pipeline Therapeutics Assessment

  • Dry Age Macular Degeneration Assessment by Product Type
  • Dry Age Macular Degeneration By Stage and Product Type
  • Dry Age Macular Degeneration Assessment by Route of Administration
  • Dry Age Macular Degeneration By Stage and Route of Administration
  • Dry Age Macular Degeneration Assessment by Molecule Type
  • Dry Age Macular Degeneration by Stage and Molecule Type

 

DelveInsight’s Dry Age Macular Degeneration Report covers around 64+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Dry Age Macular Degeneration product details are provided in the report. Download the Dry Age Macular Degeneration pipeline report to learn more about the emerging Dry Age Macular Degeneration therapies

 

Some of the key companies in the Dry Age Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Dry Age Macular Degeneration are – Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, and others.

 

Dry Age Macular Degeneration Pipeline Analysis:

The Dry Age Macular Degeneration pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dry Age Macular Degeneration with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.
  • Dry Age Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dry Age Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dry Age Macular Degeneration drugs and therapies

 

Dry Age Macular Degeneration Pipeline Market Drivers

  • Growing geriatric population and rising prevalence of AMD, robust pipeline for dry AMD treatment are some of the important factors that are fueling the Dry Age Macular Degeneration Market.

 

Dry Age Macular Degeneration Pipeline Market Barriers

  • However, lack of awareness about dry AMD, lengthy and expensive clinical trials, lack of early detection and other factors are creating obstacles in the Dry Age Macular Degeneration Market growth.

 

Scope of Dry Age Macular Degeneration Pipeline Drug Insight    

  • Coverage: Global
  • Key Dry Age Macular Degeneration Companies: Eyevensys, SanBio, Nanoscope Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Allegro Ophthalmics, Gyroscope Therapeutics, IVERIC bio, Alkeus Pharmaceuticals, Gemini Therapeutics, Eyestem, OliX Pharmaceuticals, and others
  • Key Dry Age Macular Degeneration Therapies: EYS809, SB-623, MCO-020, RPESC RPE 4W, CPCB-RPE1, Risuteganib, GT005, Zimura, ALK-001, GEM103, Eyecyte RPE, OLX301A, EYS809, and others
  • Dry Age Macular Degeneration Therapeutic Assessment: Dry Age Macular Degeneration current marketed and Dry Age Macular Degeneration emerging therapies
  • Dry Age Macular Degeneration Market Dynamics: Dry Age Macular Degeneration market drivers and Dry Age Macular Degeneration market barriers 

 

Request for Sample PDF Report for Dry Age Macular Degeneration Pipeline Assessment and clinical trials

 

Table of Contents

1. Dry Age Macular Degeneration Report Introduction

2. Dry Age Macular Degeneration Executive Summary

3. Dry Age Macular Degeneration Overview

4. Dry Age Macular Degeneration- Analytical Perspective In-depth Commercial Assessment

5. Dry Age Macular Degeneration Pipeline Therapeutics

6. Dry Age Macular Degeneration Late Stage Products (Phase II/III)

7. Dry Age Macular Degeneration Mid Stage Products (Phase II)

8. Dry Age Macular Degeneration Early Stage Products (Phase I)

9. Dry Age Macular Degeneration Preclinical Stage Products

10. Dry Age Macular Degeneration Therapeutics Assessment

11. Dry Age Macular Degeneration Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dry Age Macular Degeneration Key Companies

14. Dry Age Macular Degeneration Key Products

15. Dry Age Macular Degeneration Unmet Needs

16 . Dry Age Macular Degeneration Market Drivers and Barriers

17. Dry Age Macular Degeneration Future Perspectives and Conclusion

18. Dry Age Macular Degeneration Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *